Research Progress and Safety Controversies of Repeated Low-Level Red Light Therapy for Myopia Prevention and Control

J Ophthalmol. 2026 Nov 18;2026:9646505. doi: 10.1155/joph/9646505. eCollection 2026.

ABSTRACT

In recent years, the global prevalence of myopia has continued to rise. Complications associated with high myopia have become important risk factors for vision impairment, underscoring the need to identify safe and effective strategies for myopia prevention and control. Repeated low-level red light (RLRL) therapy, an emerging nonpharmacological intervention, has shown potential to slow axial elongation and mitigate myopia progression. This review systematically summarizes recent advances in RLRL research. Starting from the physical properties of red light, we outline putative mechanisms, including activation of mitochondrial metabolism, modulation of dopamine and nitric oxide signaling, and structural responses such as choroidal thickening and scleral remodeling. We further synthesize evidence on efficacy and parameter optimization from animal models and randomized controlled clinical studies. Although current evidence suggests that RLRL is generally well tolerated in the short term, the retinal structural effects of long-term cumulative exposure and the boundaries of dose-related safety remain debated. Future work should further clarify its safety profile and indications based on standardized treatment parameters, long-term follow-up, and multimodal structural-functional assessment.

PMID:43054670 | PMC:PMC13778768 | DOI:10.1155/joph/9646505